Akciğer Ödemli Hastaya Yaklaşım

Authors

Ümit İnci

Synopsis

This chapter examines the approach to and clinical management of patients with pulmonary edema. Pulmonary edema is a life-threatening condition requiring emergency medical intervention, characterized by excessive fluid accumulation in the alveoli, leading to dyspnea and hypoxia. In acute cases, the one-year mortality rate reaches up to 40%. Etiopathogenesis includes cardiac causes such as coronary artery disease, congestive heart failure, valvular heart diseases, arrhythmias, and hypertension, as well as noncardiac causes including ARDS, pulmonary embolism, high altitude, and toxicity. Patients typically present with respiratory distress, tachypnea, profuse sweating, cyanosis, frothy sputum, and rales. Diagnosis utilizes blood tests, arterial blood gas, natriuretic peptides (BNP), ECG, chest radiography, and echocardiography. The main goals of treatment are to achieve symptomatic relief, improve oxygenation, maintain organ perfusion, and reduce excess fluid. Following airway and circulation evaluation, oxygen support is indicated if saturation is below 92%, while noninvasive (CPAP/BiPAP) or invasive ventilation is required if hypoxemia or respiratory distress persists. Pharmacotherapy includes IV furosemide for volume overload, vasodilator nitrates with blood pressure monitoring, and inotropic agents such as dobutamine in the presence of hypotension. Routine use of morphine is not recommended.

References

Powell J, Graham D, O’Reilly S, Punton G. Acute pulmonary oedema. Nurs Stand. 2016 Feb 03;30(23):51-9; quiz 60.

Baird A. Acute pulmonary oedema - management in general practice. Aust Fam Physician 2010;39:910-4.

Colucci WS. Treatment of acute decompensated heart failure: components of therapy. UpToDate. Wolters Kluwer. Updated 5 December 2016. www.uptodate.com/contents/ treatment-of-acute-decompensated-heart-failure-components-of-therapy [cited 2017 Mar 1]

Roguin A, Behar D, Ben Ami H et al. Long-term prognosis of acute pulmonary oedema--anominous outcome. Eur J Heart Fail. 2000 Jun;2(2):137-44.

Sureka B, Bansal K, Arora A. Pulmonary edema - cardiogenic or noncardiogenic? J Family Med Prim Care. 2015 Apr-Jun;4(2):290.

Alwi I. Diagnosis and management of cardiogenic pulmonary edema. Acta Med Indones. 2010 Jul;42(3):176-84.

Guntupalli KK. Acute pulmonary edema. Cardiol Clin. 1984 May;2(2):183-200.

Sánchez Marteles M, Urrutia A. [Acute heart failure: acute cardiogenic pulmonary edema and cardiogenic shock]. Med Clin (Barc). 2014 Mar;142 Suppl 1:14-9.

Wakai A, McCabe A, Kidney R et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev. 2013 Aug 6;(8):CD005151.

Coons JC, McGraw M, Murali S. Pharmacotherapy for acute heart failure syndromes. Am J Health Syst Pharm. 2011 Jan 1;68(1):21-35.

Acute cardiogenic pulmonary oedema. In: eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2016. www.tg.org.au [cited 2017 Mar 1]

Felker GM, Lee KL, Bull DA et al; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805.

Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008 Apr;25(4):205-9.

Sjöberg F, Singer M. The medical use of oxygen: a time for critical reappraisal. J Intern Med. 2013 Dec;274(6):505-28.

Beasley R, Chien J, Douglas J et al. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: 'Swimming between the flags'. Respirology. 2015 Nov;20(8):1182-91.

Heart Failure Society of America. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 16:475-539. http://dx.doi.org/10.1016/j.cardfail.2010.04.005

Bosomworth J. Rural treatment of acute cardiogenic pulmonary edema: applying the evidence to achieve success with failure. Can J Rural Med. 2008 Summer;13(3):121-8.

Published

May 20, 2021

License

License